Ipragliflozin/sitagliptin - Astellas Pharma/MSD KK

Drug Profile

Ipragliflozin/sitagliptin - Astellas Pharma/MSD KK

Alternative Names: Ipragliflozin L-proline/sitagliptin; MK 0431J; Sitagliptin/ipragliflozin; Sitagliptin/ipragliflozin L-proline

Latest Information Update: 01 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma; MSD KK
  • Developer Astellas Pharma; Kotobuki Pharmaceutical; MSD KK
  • Class Antihyperglycaemics; Glucosides; Pyrazines; Small molecules; Thiophenes; Triazoles
  • Mechanism of Action CD26 antigen inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Type 2 diabetes mellitus

Most Recent Events

  • 26 May 2017 Chemical structure information added
  • 01 May 2017 Preregistration for Type-2 diabetes mellitus in Japan (PO)
  • 15 Apr 2015 Early research in Type-2 diabetes mellitus in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top